

Global Short-acting Recombinant Human Erythropoietin Injections Market Growth 2026-2032

<https://marketpublishers.com/r/GEA319DFBA9DEN.html>

Date: September 2026

Pages: 117

Price: US\$ 3,660.00 (Single User License)

ID: GEA319DFBA9DEN

Abstracts

The global Short-acting Recombinant Human Erythropoietin Injections market size is predicted to grow from US\$ 10510 million in 2025 to US\$ 16130 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

United States market for Short-acting Recombinant Human Erythropoietin Injections is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Short-acting Recombinant Human Erythropoietin Injections is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Short-acting Recombinant Human Erythropoietin Injections is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Short-acting Recombinant Human Erythropoietin Injections players cover Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Short-acting Recombinant

Human Erythropoietin Injections Industry Forecast” looks at past sales and reviews total world Short-acting Recombinant Human Erythropoietin Injections sales in 2025, providing a comprehensive analysis by region and market sector of projected Short-acting Recombinant Human Erythropoietin Injections sales for 2026 through 2032. With Short-acting Recombinant Human Erythropoietin Injections sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Short-acting Recombinant Human Erythropoietin Injections industry.

This Insight Report provides a comprehensive analysis of the global Short-acting Recombinant Human Erythropoietin Injections landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short-acting Recombinant Human Erythropoietin Injections portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Short-acting Recombinant Human Erythropoietin Injections market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short-acting Recombinant Human Erythropoietin Injections and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short-acting Recombinant Human Erythropoietin Injections.

This report presents a comprehensive overview, market shares, and growth opportunities of Short-acting Recombinant Human Erythropoietin Injections market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

Segmentation by Application:

Anemia

Kidney Disorders

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Amgen

Johnson & Johnson

Roche

Kyowa Kirin

LG Chem

Daewoong Pharmaceutical

Wockhardt

CJ Healthcare

3SBio

Kexing Biopharm

Harbin Pharmaceutical Group

Beijing Four Rings Bio-Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Short-acting Recombinant Human Erythropoietin Injections market?

What factors are driving Short-acting Recombinant Human Erythropoietin Injections market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Short-acting Recombinant Human Erythropoietin Injections market opportunities vary by end market size?

How does Short-acting Recombinant Human Erythropoietin Injections break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Short-acting Recombinant Human Erythropoietin Injections Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Injections by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Injections by Country/Region, 2021, 2025 & 2032
- 2.2 Short-acting Recombinant Human Erythropoietin Injections Segment by Type
 - 2.2.1 Epoetin-alfa
 - 2.2.2 Epoetin-beta
 - 2.2.3 Darbepoetin-alfa
 - 2.2.4 Others
 - 2.2.5 Short-acting Recombinant Human Erythropoietin Injections Sales by Type
 - 2.2.5.1 Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Short-acting Recombinant Human Erythropoietin Injections Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Short-acting Recombinant Human Erythropoietin Injections Sale Price by Type (2021-2026)
- 2.3 Short-acting Recombinant Human Erythropoietin Injections Segment by Application
 - 2.3.1 Anemia
 - 2.3.2 Kidney Disorders
 - 2.3.3 Others

- 2.3.4 Short-acting Recombinant Human Erythropoietin Injections Sales by Application
 - 2.3.4.1 Global Short-acting Recombinant Human Erythropoietin Injections Sale Market Share by Application (2021-2026)
 - 2.3.4.2 Global Short-acting Recombinant Human Erythropoietin Injections Revenue and Market Share by Application (2021-2026)
 - 2.3.4.3 Global Short-acting Recombinant Human Erythropoietin Injections Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

- 3.1 Global Short-acting Recombinant Human Erythropoietin Injections Breakdown Data by Company
 - 3.1.1 Global Short-acting Recombinant Human Erythropoietin Injections Annual Sales by Company (2021-2026)
 - 3.1.2 Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Company (2021-2026)
- 3.2 Global Short-acting Recombinant Human Erythropoietin Injections Annual Revenue by Company (2021-2026)
 - 3.2.1 Global Short-acting Recombinant Human Erythropoietin Injections Revenue by Company (2021-2026)
 - 3.2.2 Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Company (2021-2026)
- 3.3 Global Short-acting Recombinant Human Erythropoietin Injections Sale Price by Company
- 3.4 Key Manufacturers Short-acting Recombinant Human Erythropoietin Injections Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Short-acting Recombinant Human Erythropoietin Injections Product Location Distribution
 - 3.4.2 Players Short-acting Recombinant Human Erythropoietin Injections Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN INJECTIONS BY GEOGRAPHIC REGION

4.1 World Historic Short-acting Recombinant Human Erythropoietin Injections Market Size by Geographic Region (2021-2026)

4.1.1 Global Short-acting Recombinant Human Erythropoietin Injections Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Short-acting Recombinant Human Erythropoietin Injections Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Short-acting Recombinant Human Erythropoietin Injections Market Size by Country/Region (2021-2026)

4.2.1 Global Short-acting Recombinant Human Erythropoietin Injections Annual Sales by Country/Region (2021-2026)

4.2.2 Global Short-acting Recombinant Human Erythropoietin Injections Annual Revenue by Country/Region (2021-2026)

4.3 Americas Short-acting Recombinant Human Erythropoietin Injections Sales Growth

4.4 APAC Short-acting Recombinant Human Erythropoietin Injections Sales Growth

4.5 Europe Short-acting Recombinant Human Erythropoietin Injections Sales Growth

4.6 Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales Growth

5 AMERICAS

5.1 Americas Short-acting Recombinant Human Erythropoietin Injections Sales by Country

5.1.1 Americas Short-acting Recombinant Human Erythropoietin Injections Sales by Country (2021-2026)

5.1.2 Americas Short-acting Recombinant Human Erythropoietin Injections Revenue by Country (2021-2026)

5.2 Americas Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026)

5.3 Americas Short-acting Recombinant Human Erythropoietin Injections Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Short-acting Recombinant Human Erythropoietin Injections Sales by Region

6.1.1 APAC Short-acting Recombinant Human Erythropoietin Injections Sales by

Region (2021-2026)

6.1.2 APAC Short-acting Recombinant Human Erythropoietin Injections Revenue by Region (2021-2026)

6.2 APAC Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026)

6.3 APAC Short-acting Recombinant Human Erythropoietin Injections Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Short-acting Recombinant Human Erythropoietin Injections by Country

7.1.1 Europe Short-acting Recombinant Human Erythropoietin Injections Sales by Country (2021-2026)

7.1.2 Europe Short-acting Recombinant Human Erythropoietin Injections Revenue by Country (2021-2026)

7.2 Europe Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026)

7.3 Europe Short-acting Recombinant Human Erythropoietin Injections Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections by Country

8.1.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales by Country (2021-2026)

8.1.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections

Revenue by Country (2021-2026)

8.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections

Sales by Type (2021-2026)

8.3 Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections

Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Injections

10.3 Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Injections

10.4 Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Injections

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Short-acting Recombinant Human Erythropoietin Injections Distributors

11.3 Short-acting Recombinant Human Erythropoietin Injections Customer

12 WORLD FORECAST REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN INJECTIONS BY GEOGRAPHIC REGION

12.1 Global Short-acting Recombinant Human Erythropoietin Injections Market Size

Forecast by Region

12.1.1 Global Short-acting Recombinant Human Erythropoietin Injections Forecast by Region (2027-2032)

12.1.2 Global Short-acting Recombinant Human Erythropoietin Injections Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Short-acting Recombinant Human Erythropoietin Injections Forecast by Type (2027-2032)

12.7 Global Short-acting Recombinant Human Erythropoietin Injections Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Amgen

13.1.1 Amgen Company Information

13.1.2 Amgen Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

13.1.3 Amgen Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Amgen Main Business Overview

13.1.5 Amgen Latest Developments

13.2 Johnson & Johnson

13.2.1 Johnson & Johnson Company Information

13.2.2 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

13.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Johnson & Johnson Main Business Overview

13.2.5 Johnson & Johnson Latest Developments

13.3 Roche

13.3.1 Roche Company Information

13.3.2 Roche Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

13.3.3 Roche Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Roche Main Business Overview

- 13.3.5 Roche Latest Developments
- 13.4 Kyowa Kirin
 - 13.4.1 Kyowa Kirin Company Information
 - 13.4.2 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Kyowa Kirin Main Business Overview
 - 13.4.5 Kyowa Kirin Latest Developments
- 13.5 LG Chem
 - 13.5.1 LG Chem Company Information
 - 13.5.2 LG Chem Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 LG Chem Main Business Overview
 - 13.5.5 LG Chem Latest Developments
- 13.6 Daewoong Pharmaceutical
 - 13.6.1 Daewoong Pharmaceutical Company Information
 - 13.6.2 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Daewoong Pharmaceutical Main Business Overview
 - 13.6.5 Daewoong Pharmaceutical Latest Developments
- 13.7 Wockhardt
 - 13.7.1 Wockhardt Company Information
 - 13.7.2 Wockhardt Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Wockhardt Main Business Overview
 - 13.7.5 Wockhardt Latest Developments
- 13.8 CJ Healthcare
 - 13.8.1 CJ Healthcare Company Information
 - 13.8.2 CJ Healthcare Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.8.4 CJ Healthcare Main Business Overview
- 13.8.5 CJ Healthcare Latest Developments
- 13.9 3SBio
 - 13.9.1 3SBio Company Information
 - 13.9.2 3SBio Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.9.3 3SBio Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 3SBio Main Business Overview
 - 13.9.5 3SBio Latest Developments
- 13.10 Kexing Biopharm
 - 13.10.1 Kexing Biopharm Company Information
 - 13.10.2 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.10.4 Kexing Biopharm Main Business Overview
 - 13.10.5 Kexing Biopharm Latest Developments
- 13.11 Harbin Pharmaceutical Group
 - 13.11.1 Harbin Pharmaceutical Group Company Information
 - 13.11.2 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.11.4 Harbin Pharmaceutical Group Main Business Overview
 - 13.11.5 Harbin Pharmaceutical Group Latest Developments
- 13.12 Beijing Four Rings Bio-Pharmaceutical
 - 13.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
 - 13.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications
 - 13.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.12.4 Beijing Four Rings Bio-Pharmaceutical Main Business Overview
 - 13.12.5 Beijing Four Rings Bio-Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Short-acting Recombinant Human Erythropoietin Injections Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Short-acting Recombinant Human Erythropoietin Injections Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Epoetin-alfa

Table 4. Major Players of Epoetin-beta

Table 5. Major Players of Darbepoetin-alfa

Table 6. Major Players of Others

Table 7. Global Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026) & (K Units)

Table 8. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Type (2021-2026)

Table 9. Global Short-acting Recombinant Human Erythropoietin Injections Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Type (2021-2026)

Table 11. Global Short-acting Recombinant Human Erythropoietin Injections Sale Price by Type (2021-2026) & (US\$/Unit)

Table 12. Global Short-acting Recombinant Human Erythropoietin Injections Sale by Application (2021-2026) & (K Units)

Table 13. Global Short-acting Recombinant Human Erythropoietin Injections Sale Market Share by Application (2021-2026)

Table 14. Global Short-acting Recombinant Human Erythropoietin Injections Revenue by Application (2021-2026) & (\$ million)

Table 15. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Application (2021-2026)

Table 16. Global Short-acting Recombinant Human Erythropoietin Injections Sale Price by Application (2021-2026) & (US\$/Unit)

Table 17. Global Short-acting Recombinant Human Erythropoietin Injections Sales by Company (2021-2026) & (K Units)

Table 18. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Company (2021-2026)

Table 19. Global Short-acting Recombinant Human Erythropoietin Injections Revenue by Company (2021-2026) & (\$ millions)

Table 20. Global Short-acting Recombinant Human Erythropoietin Injections Revenue

Market Share by Company (2021-2026)

Table 21. Global Short-acting Recombinant Human Erythropoietin Injections Sale Price by Company (2021-2026) & (US\$/Unit)

Table 22. Key Manufacturers Short-acting Recombinant Human Erythropoietin Injections Producing Area Distribution and Sales Area

Table 23. Players Short-acting Recombinant Human Erythropoietin Injections Products Offered

Table 24. Short-acting Recombinant Human Erythropoietin Injections Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Short-acting Recombinant Human Erythropoietin Injections Sales by Geographic Region (2021-2026) & (K Units)

Table 28. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share Geographic Region (2021-2026)

Table 29. Global Short-acting Recombinant Human Erythropoietin Injections Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 30. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Geographic Region (2021-2026)

Table 31. Global Short-acting Recombinant Human Erythropoietin Injections Sales by Country/Region (2021-2026) & (K Units)

Table 32. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Country/Region (2021-2026)

Table 33. Global Short-acting Recombinant Human Erythropoietin Injections Revenue by Country/Region (2021-2026) & (\$ millions)

Table 34. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Country/Region (2021-2026)

Table 35. Americas Short-acting Recombinant Human Erythropoietin Injections Sales by Country (2021-2026) & (K Units)

Table 36. Americas Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Country (2021-2026)

Table 37. Americas Short-acting Recombinant Human Erythropoietin Injections Revenue by Country (2021-2026) & (\$ millions)

Table 38. Americas Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026) & (K Units)

Table 39. Americas Short-acting Recombinant Human Erythropoietin Injections Sales by Application (2021-2026) & (K Units)

Table 40. APAC Short-acting Recombinant Human Erythropoietin Injections Sales by Region (2021-2026) & (K Units)

Table 41. APAC Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Region (2021-2026)

Table 42. APAC Short-acting Recombinant Human Erythropoietin Injections Revenue by Region (2021-2026) & (\$ millions)

Table 43. APAC Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026) & (K Units)

Table 44. APAC Short-acting Recombinant Human Erythropoietin Injections Sales by Application (2021-2026) & (K Units)

Table 45. Europe Short-acting Recombinant Human Erythropoietin Injections Sales by Country (2021-2026) & (K Units)

Table 46. Europe Short-acting Recombinant Human Erythropoietin Injections Revenue by Country (2021-2026) & (\$ millions)

Table 47. Europe Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026) & (K Units)

Table 48. Europe Short-acting Recombinant Human Erythropoietin Injections Sales by Application (2021-2026) & (K Units)

Table 49. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales by Country (2021-2026) & (K Units)

Table 50. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Country (2021-2026)

Table 51. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales by Type (2021-2026) & (K Units)

Table 52. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales by Application (2021-2026) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Short-acting Recombinant Human Erythropoietin Injections

Table 54. Key Market Challenges & Risks of Short-acting Recombinant Human Erythropoietin Injections

Table 55. Key Industry Trends of Short-acting Recombinant Human Erythropoietin Injections

Table 56. Short-acting Recombinant Human Erythropoietin Injections Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Short-acting Recombinant Human Erythropoietin Injections Distributors List

Table 59. Short-acting Recombinant Human Erythropoietin Injections Customer List

Table 60. Global Short-acting Recombinant Human Erythropoietin Injections Sales Forecast by Region (2027-2032) & (K Units)

Table 61. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 62. Americas Short-acting Recombinant Human Erythropoietin Injections Sales

Forecast by Country (2027-2032) & (K Units)

Table 63. Americas Short-acting Recombinant Human Erythropoietin Injections Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 64. APAC Short-acting Recombinant Human Erythropoietin Injections Sales Forecast by Region (2027-2032) & (K Units)

Table 65. APAC Short-acting Recombinant Human Erythropoietin Injections Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 66. Europe Short-acting Recombinant Human Erythropoietin Injections Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Europe Short-acting Recombinant Human Erythropoietin Injections Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales Forecast by Country (2027-2032) & (K Units)

Table 69. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 70. Global Short-acting Recombinant Human Erythropoietin Injections Sales Forecast by Type (2027-2032) & (K Units)

Table 71. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 72. Global Short-acting Recombinant Human Erythropoietin Injections Sales Forecast by Application (2027-2032) & (K Units)

Table 73. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 74. Amgen Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 75. Amgen Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 76. Amgen Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 77. Amgen Main Business

Table 78. Amgen Latest Developments

Table 79. Johnson & Johnson Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 80. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 81. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 82. Johnson & Johnson Main Business

Table 83. Johnson & Johnson Latest Developments

Table 84. Roche Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 85. Roche Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 86. Roche Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 87. Roche Main Business

Table 88. Roche Latest Developments

Table 89. Kyowa Kirin Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 90. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 91. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 92. Kyowa Kirin Main Business

Table 93. Kyowa Kirin Latest Developments

Table 94. LG Chem Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 95. LG Chem Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 96. LG Chem Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 97. LG Chem Main Business

Table 98. LG Chem Latest Developments

Table 99. Daewoong Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 100. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 101. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 102. Daewoong Pharmaceutical Main Business

Table 103. Daewoong Pharmaceutical Latest Developments

Table 104. Wockhardt Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 105. Wockhardt Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 106. Wockhardt Short-acting Recombinant Human Erythropoietin Injections Sales

(K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 107. Wockhardt Main Business

Table 108. Wockhardt Latest Developments

Table 109. CJ Healthcare Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 110. CJ Healthcare Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 111. CJ Healthcare Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 112. CJ Healthcare Main Business

Table 113. CJ Healthcare Latest Developments

Table 114. 3SBio Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 115. 3SBio Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 116. 3SBio Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 117. 3SBio Main Business

Table 118. 3SBio Latest Developments

Table 119. Kexing Biopharm Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 120. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 121. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 122. Kexing Biopharm Main Business

Table 123. Kexing Biopharm Latest Developments

Table 124. Harbin Pharmaceutical Group Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 125. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 126. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 127. Harbin Pharmaceutical Group Main Business

Table 128. Harbin Pharmaceutical Group Latest Developments

Table 129. Beijing Four Rings Bio-Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Injections Manufacturing Base, Sales Area and Its Competitors

Table 130. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Product Portfolios and Specifications

Table 131. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Injections Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 132. Beijing Four Rings Bio-Pharmaceutical Main Business

Table 133. Beijing Four Rings Bio-Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Short-acting Recombinant Human Erythropoietin Injections

Figure 2. Short-acting Recombinant Human Erythropoietin Injections Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Short-acting Recombinant Human Erythropoietin Injections Sales Growth Rate 2021-2032 (K Units)

Figure 7. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. Short-acting Recombinant Human Erythropoietin Injections Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Country/Region (2025)

Figure 10. Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Epoetin-alfa

Figure 12. Product Picture of Epoetin-beta

Figure 13. Product Picture of Darbepoetin-alfa

Figure 14. Product Picture of Others

Figure 15. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Type in 2026

Figure 16. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Type (2021-2026)

Figure 17. Short-acting Recombinant Human Erythropoietin Injections Consumed in Anemia

Figure 18. Global Short-acting Recombinant Human Erythropoietin Injections Market: Anemia (2021-2026) & (K Units)

Figure 19. Short-acting Recombinant Human Erythropoietin Injections Consumed in Kidney Disorders

Figure 20. Global Short-acting Recombinant Human Erythropoietin Injections Market: Kidney Disorders (2021-2026) & (K Units)

Figure 21. Short-acting Recombinant Human Erythropoietin Injections Consumed in Others

Figure 22. Global Short-acting Recombinant Human Erythropoietin Injections Market:

Others (2021-2026) & (K Units)

Figure 23. Global Short-acting Recombinant Human Erythropoietin Injections Sale Market Share by Application (2025)

Figure 24. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Application in 2026

Figure 25. Short-acting Recombinant Human Erythropoietin Injections Sales by Company in 2026 (K Units)

Figure 26. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Company in 2026

Figure 27. Short-acting Recombinant Human Erythropoietin Injections Revenue by Company in 2026 (\$ millions)

Figure 28. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Company in 2026

Figure 29. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Geographic Region (2021-2026)

Figure 30. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Geographic Region in 2026

Figure 31. Americas Short-acting Recombinant Human Erythropoietin Injections Sales 2021-2026 (K Units)

Figure 32. Americas Short-acting Recombinant Human Erythropoietin Injections Revenue 2021-2026 (\$ millions)

Figure 33. APAC Short-acting Recombinant Human Erythropoietin Injections Sales 2021-2026 (K Units)

Figure 34. APAC Short-acting Recombinant Human Erythropoietin Injections Revenue 2021-2026 (\$ millions)

Figure 35. Europe Short-acting Recombinant Human Erythropoietin Injections Sales 2021-2026 (K Units)

Figure 36. Europe Short-acting Recombinant Human Erythropoietin Injections Revenue 2021-2026 (\$ millions)

Figure 37. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales 2021-2026 (K Units)

Figure 38. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Revenue 2021-2026 (\$ millions)

Figure 39. Americas Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Country in 2026

Figure 40. Americas Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Country (2021-2026)

Figure 41. Americas Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Type (2021-2026)

Figure 42. Americas Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Application (2021-2026)

Figure 43. United States Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 44. Canada Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 45. Mexico Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 46. Brazil Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 47. APAC Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Region in 2026

Figure 48. APAC Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Region (2021-2026)

Figure 49. APAC Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Type (2021-2026)

Figure 50. APAC Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Application (2021-2026)

Figure 51. China Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 52. Japan Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 53. South Korea Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 54. Southeast Asia Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 55. India Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 56. Australia Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 57. China Taiwan Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 58. Europe Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Country in 2026

Figure 59. Europe Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share by Country (2021-2026)

Figure 60. Europe Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Type (2021-2026)

Figure 61. Europe Short-acting Recombinant Human Erythropoietin Injections Sales

Market Share by Application (2021-2026)

Figure 62. Germany Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 63. France Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 64. UK Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 65. Italy Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 66. Russia Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 67. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Country (2021-2026)

Figure 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Type (2021-2026)

Figure 69. Middle East & Africa Short-acting Recombinant Human Erythropoietin Injections Sales Market Share by Application (2021-2026)

Figure 70. Egypt Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 71. South Africa Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 72. Israel Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 73. Turkey Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 74. GCC Countries Short-acting Recombinant Human Erythropoietin Injections Revenue Growth 2021-2026 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Injections in 2026

Figure 76. Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Injections

Figure 77. Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Injections

Figure 78. Channels of Distribution

Figure 79. Global Short-acting Recombinant Human Erythropoietin Injections Sales Market Forecast by Region (2027-2032)

Figure 80. Global Short-acting Recombinant Human Erythropoietin Injections Revenue Market Share Forecast by Region (2027-2032)

Figure 81. Global Short-acting Recombinant Human Erythropoietin Injections Sales

Market Share Forecast by Type (2027-2032)

Figure 82. Global Short-acting Recombinant Human Erythropoietin Injections Revenue

Market Share Forecast by Type (2027-2032)

Figure 83. Global Short-acting Recombinant Human Erythropoietin Injections Sales

Market Share Forecast by Application (2027-2032)

Figure 84. Global Short-acting Recombinant Human Erythropoietin Injections Revenue

Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Short-acting Recombinant Human Erythropoietin Injections Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GEA319DFBA9DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEA319DFBA9DEN.html>